title: Combined blockade of VEGFR-3 and VLA-1 markedly promotes high-risk corneal transplant survival.
abstract: PURPOSE. High-risk corneal transplantation refers to grafting performed on inflamed and highly vascularized host beds. It represents a clinical dilemma because the rejection rate can be as high as 90%, irrespective of current treatment modalities. This study was conducted to investigate whether combined blockade of VEGFR-3 (vascular endothelial growth factor receptor-3) and VLA-1 (very late antigen-1) promotes high-risk transplant survival and how it correlates with corneal lymphangiogenesis and hemangiogenesis before and after transplantation. METHODS. High-risk corneal transplantation was performed between normal C57BL/6 (donor) and inflamed BALB/c (recipient) mice. The recipients were randomized to receive intraperitoneal injections of VEGFR-3 and VLA-1-neutralizing antibodies or their controls twice a week for up to 8 weeks after transplantation. Corneal grafts were evaluated by ophthalmic slit-lamp biomicroscopy and analyzed by Kaplan-Meier survival curve. Additionally, whole-mount corneas before and after transplantation were examined by immunofluorescent microscopic assays, and the correlation between lymphatic or blood vessel distribution and transplant outcome was analyzed. RESULTS. The combined blockade markedly promotes 90% survival of high-risk transplants. This strategy specifically modified host beds by selective inhibition of lymphangiogenesis but not hemangiogenesis. A strong correlation was also identified between high-risk transplant rejection and severe lymphatic invasion reaching the donor-graft border. CONCLUSIONS. These novel findings not only provide a new and potentially powerful strategy to promote high-risk transplant survival, they also confirm a critical role of high-degree lymphangiogenesis in mediating high-risk transplant rejection. Results from this study may also shed new light on our understanding and management of other lymphatic- and immune-related diseases in general.
authors.affiliation: Center for Eye Disease and Development, Program in Vision Science and School of Optometry, University of California, Berkeley, USA.
authors.forename: Hui
authors.initials: H
authors.lastname: Zhang
authors.forename: Sammy
authors.initials: S
authors.lastname: Grimaldo
authors.forename: Don
authors.initials: D
authors.lastname: Yuen
authors.forename: Lu
authors.initials: L
authors.lastname: Chen
mesh_terms: D000818:Animals; D057134:Antibodies, Neutralizing / Q000494:pharmacology*; D003315:Cornea / Q000098:blood supply; D016510:Corneal Neovascularization / Q000378:metabolism / Q000503:physiopathology / Q000601:surgery*; D016039:Corneal Transplantation; D006085:Graft Survival / Q000502:physiology*; D007274:Injections, Intraperitoneal; D039222:Integrin alpha1beta1 / Q000037:antagonists & inhibitors*; D042583:Lymphangiogenesis / Q000187:drug effects; D042601:Lymphatic Vessels / Q000187:drug effects / Q000378:metabolism; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D008856:Microscopy, Fluorescence; D012307:Risk Factors; D040321:Vascular Endothelial Growth Factor Receptor-3 / Q000037:antagonists & inhibitors*
chemical_list: D057134:Antibodies, Neutralizing; D039222:Integrin alpha1beta1; D040321:Vascular Endothelial Growth Factor Receptor-3